Investigating NX-2127, a BTK Degrader, in B-Cell Malignancies
Researchers at the National Institutes of Health (NIH) are testing NX-2127, an oral drug that degrades a protein in cancer cells called Bruton's tyrosine kinase (BTK), instead of inhibiting or blocking it like other drugs. NX-2127 may also stimulate your immune T-cells to attack the cancer.
Eligible Participants:
- Are 18 years or older;
- Are diagnosed with one of the B-cell malignancies as listed below;
- Have relapsed after at least two prior systemic therapies for:
- Chronic Lymphocytic Leukemia (CLL)
- Small Lymphocytic Lymphoma (SLL)
- Waldenström Macroglobulinemia (WM) (only one previous treatment required)
- Mantle Cell Lymphoma (MCL)
- Marginal Zone Lymphoma (MZL)
- Follicular Lymphoma (FL)
- Diffuse Large B-cell Lymphoma (DLBCL)
Study Includes:
- Taking NX-2127 by mouth daily for 28-day cycles
- Diagnostic procedures such as blood tests, bone marrow biopsies and CT scans (or PET-CTs as appropriate), lymph node biopsies, EKG, and echocardiogram
- Weekly outpatient visits during the first 8 weeks, and then approximately every 4 weeks after that
Your participation is at no cost, and travel assistance may be available.
The NIH Clinical Center, America's Research Hospital, is located in Bethesda, MD on the Metro red line (Medical Center stop).
For more information:
NIH Clinical Center Office of Patient Recruitment
800-411-1222
TTY users dial 7-1-1
Email: ccopr@nigh.gov
Or go online:
https://go.usa.gov/xuPDr
Refer to study # 000326-H
Department of Health and Human Services
National Institutes of Health Clinical Center (CC)
National Heart, Lung and Blood Institute (NHLBI)